| 2026-08-17 | Presentation | LUGANO Topline Data Presentation |
| 2026-08-17 | Press release | EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet |
| 2026-08-14 | Press release | EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
| 2026-08-05 | Press release | EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments |
| 2026-08-04 | Presentation | EyePoint Investor Presentation August 2026 |
| 2026-07-30 | Press release | EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME) |
| 2026-07-16 | Press release | EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
| 2026-07-13 | Press release | EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer |
| 2026-06-16 | Press release | EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
| 2026-05-19 | Press release | EyePoint Announces Participation at Upcoming Investor Conferences |
| 2026-05-18 | Press release | EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
| 2026-05-14 | Press release | EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Conf |
| 2026-05-06 | Press release | EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments |
| 2026-04-29 | Press release | EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026 |
| 2026-03-02 | Press release | EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic |
| 2026-02-25 | Press release | EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026 |
| 2026-02-24 | Press release | EyePoint Announces Participation at Upcoming Investor Conferences |
| 2026-02-05 | Press release | EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 |
| 2026-01-07 | Press release | EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 |
| 2025-12-17 | Press release | EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 2025-12-16 | Press release | EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
| 2025-11-03 | Press release | EyePoint Announces Participation at Upcoming Investor Conferences |
| 2025-10-14 | Press release | EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema |
| 2025-08-26 | Press release | EyePoint Announces Participation at Upcoming Investor Conferences |
| 2025-08-06 | Press release | EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference |
| 2025-07-29 | Press release | EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration |
| 2025-05-28 | Press release | EyePoint Announces Participation at Upcoming Investor Conferences |
| 2025-05-27 | Press release | EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degen |
| 2025-05-13 | Press release | EyePoint Announces Participation at Upcoming Investor Conferences |
| 2025-03-27 | Press release | EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference |
| 2025-03-05 | Press release | EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments |
| 2025-03-04 | Press release | EyePoint Announces Participation at Upcoming Investor Conferences |
| 2025-02-26 | Press release | EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025 |
| 2025-02-25 | Press release | EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference |
| 2025-02-05 | Press release | EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Ede |
| 2025-01-30 | Press release | EyePoint to Present at Guggenheim SMID Cap Biotech Conference |
| 2025-01-13 | Press release | EyePoint Provides Company Update and Anticipated Development Milestones for 2025 |
| 2024-12-17 | Press release | EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
| 2024-12-04 | Press release | EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of We |
| 2024-11-04 | Press release | EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences |